Potassium
Of 12,185 on-market potassium products in the January 2026 DSLD dump, the median declared dose is 99 elemental mg, and 70.1% list unspecified/undisclosed form as the primary form.
Form share
Of 11,188 products with an identifiable primary form, here is the share held by each form of Potassium on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| unspecified/undisclosed form | Unrated | 7,843 | 70.1% |
| Potassium Citrate | Tier 1 | 1,232 | 11.0% |
| Potassium Chloride | Tier 1 | 1,232 | 11.0% |
| Potassium Bicarbonate | Unrated | 332 | 3.0% |
| Potassium Aspartate | Tier 2 | 310 | 2.8% |
| Potassium Gluconate | Tier 2 | 239 | 2.1% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (elemental mg), among 11,996 products with a disclosed amount, against the RDA of 3400.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 90.0% of products fall below the fairy-dust threshold (312 mg, 20% of the studied low dose).
- 1.2% of products don't disclose an amount because Potassium is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (elemental mg) to see exactly how it compares to the 11,812 on-market potassium products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for potassium on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses only "Potassium" with no salt form (largest bucket, ~10,901 rows).
Elemental fraction: 52.4% (KCl, MW 74.55)
Standard reference form in most potassium-supplementation trials (the Whelton abstract does not itemise salts).
Source: Whelton PK et al. 1997, JAMA 277(20):1624-32, PMID 9168293
Elemental fraction: 36.2% (K3C6H5O7 x H2O, monohydrate (standard USP form, MW 324.41; anhydrous at 0.383 also exists))
Treated as equivalent to potassium chloride (tier 1) on the basis of reported bioequivalence in absorption, but no primary absorption/PK comparison was verified; preferred clinically for kidney-stone prevention/urinary alkalinization rather than for an absorption advantage.
Source: none verified for the absorption claim (Sakhaee K et al. 1991, J Clin Endocrinol Metab 72(2):396-400, PMID 1899422 compares potassium salts on renal citrate excretion, not absorption)
Elemental fraction: 39.1% (KHCO3, anhydrous (no commercial hydrate))
Alkaline potassium salt used in bone-health trials (KHCO3 60-120 mmol/day; Sebastian 1994), but there are no head-to-head absorption data. In Dawson-Hughes 2009 the effects on urinary calcium and bone resorption were attributed to bicarbonate, not potassium, so bone-marker effects do not demonstrate potassium bioavailability.
Source: Sebastian A et al. 1994, N Engl J Med 330(25):1776-81, PMID 8190153; Dawson-Hughes B et al. 2009, J Clin Endocrinol Metab 94(1):96-102, PMID 18940881
Elemental fraction: 16.7% (K(C6H11O7), MW 234.26)
No dedicated comparative bioavailability citation located; assumed acceptable as a simple soluble monovalent salt.
Source: none located (no comparative bioavailability study found)
Elemental fraction: 22.8% (Monopotassium L-aspartate, C4H6KNO4, MW 171.19, CAS 1115-63-5 (cross-checked against a commercial 99mg-K-per-450mg-capsule label claim, consistent with this stoichiometry))
No dedicated comparative bioavailability study located; assumed acceptable given the label cross-check.
Source: none located (no comparative bioavailability study found)
Reference values
- RDA (adult): 3400 elemental mg — Adequate Intake (2019 NASEM revision, supersedes the older 4700mg figure): 3400mg (men); 2600mg (women)
- Tolerable Upper Intake Level (adult): not established — Not established for apparently healthy individuals (risk remains in renal impairment)
- Studied clinical dose range: 1560–4700 mg
- Whelton PK et al. 1997, JAMA 277(20):1624-32, PMID 9168293 -- meta-analysis of 33 RCTs (n=2,609); pooled ~-3.1mmHg systolic/-2.0mmHg diastolic BP reduction after excluding one extreme trial, with the effect enhanced at high sodium intake. The abstract gives no dose range: the 1560-4700mg range (40-120 mmol/day) is the commonly-cited trial range, not independently confirmed against the full paper's per-trial dose breakdown; 60-120 mmol/day KHCO3 was used by Sebastian A et al. 1994, NEJM 330(25):1776-81, PMID 8190153.
- Note: studied_dose_high uses the older, pre-2019 AI figure (4700mg) as the top of the commonly-cited trial range; treat as approximate.